Bone Marrow & Stem Cell Transplant

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

A scoring tool combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

FBEM conditioning in ALL alloHSCT yielded 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Rawan Faramand, MD, discusses how reducing the cost of GVHD therapy could benefit health systems.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

Rawan Faramand, MD, explains how a cost analysis supported Orca-T engineered graft by reducing the need for GVHD therapy vs standard prophylaxis.

Amandeep Salhotra, MD, discusses preclinical findings that could support the addition of a BCL2 inhibitor to address acute or chronic graft-vs-host disease.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

In the ARES trial, MaaT013 led to improvement in refractory lower GI chronic GVHD, a key unmet need in patients receiving hematopoietic cell transplant.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

An ongoing trial could establish new standard of care for chronic graft-vs-host disease.

Amandeep Salhotra, MD, discusses a retrospective observational analysis comparing Orca-T to standard graft with posttransplant cyclophosphamide.

The ACCESS study of post-transplant cyclophosphamide in stem cell transplant showed that even 6/8 and 5/8 HLA matches can be considered as donors.

Longer follow-up of patients receiving a modern prophylactic regimen shows positive outcomes for preventing chronic GVHD and relapse after stem cell transplant.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

Phase 2 interim safety data presented at the EBMT 2026 Annual Meeting suggest no additive toxicity with the novel combination chronic GVHD regimen.

Adding itacitinib to posttransplant cyclophosphamide and tacrolimus proved safe and well tolerated, with low GVHD rates and no nonrelapse mortality.

ABC trial interim results demonstrate effective, short-duration prophylaxis without conventional immunosuppressants and with dose-reduced cyclophosphamide.

Most patients with heavily pretreated chronic GVHD experienced clinical benefit with axatilimab, with the majority continuing treatment after approval.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.